HUP9901191A2 - Cell line producing analgesic compounds for treating pain - Google Patents

Cell line producing analgesic compounds for treating pain

Info

Publication number
HUP9901191A2
HUP9901191A2 HU9901191A HUP9901191A HUP9901191A2 HU P9901191 A2 HUP9901191 A2 HU P9901191A2 HU 9901191 A HU9901191 A HU 9901191A HU P9901191 A HUP9901191 A HU P9901191A HU P9901191 A2 HUP9901191 A2 HU P9901191A2
Authority
HU
Hungary
Prior art keywords
cell line
treating pain
line producing
analgesic compounds
pain
Prior art date
Application number
HU9901191A
Other languages
Hungarian (hu)
Inventor
Joel Saydoff
Shou Wong
Original Assignee
Cytotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytotherapeutics, Inc. filed Critical Cytotherapeutics, Inc.
Publication of HUP9901191A2 publication Critical patent/HUP9901191A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70—Enkephalins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány tárgya egy stabilan transzfőrmált sejt, mely legalább egyfájdalőmcsillapító hatású vegyületet termel a következő csőpőrtőkmindegyikéből: endőrfinők, enkefalinők és katekőlaminők. A találmánymagában főglalja a szóban főrgó sejt előállítását, valamint a módszertbiőlógiailag mesterséges szerv létrehőzására, mely tartalmazza atranszfőrmált sejtek kapszűlába zárását, és egy őperációs eljárást,mellyel a kapszűlát a fájdalőm kezelése érdekében a betegekbeimplantálják az előnyben részesített sűbarachnőidális térbe. ŕThe subject of the invention is a stably transformed cell that produces at least one pain-relieving compound from each of the following tubeworms: spp. The invention itself focuses on the production of the spinning cell in question, as well as the methodology for the creation of the biologically artificial organ, which includes the encapsulation of the transformed cells, and a surgical procedure in which the capsule is implanted in the patients' preferred narrow arachnoid space in order to treat the pain. ŕ

HU9901191A 1995-06-07 1996-06-07 Cell line producing analgesic compounds for treating pain HUP9901191A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48191795A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
HUP9901191A2 true HUP9901191A2 (en) 1999-08-30

Family

ID=23913905

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901191A HUP9901191A2 (en) 1995-06-07 1996-06-07 Cell line producing analgesic compounds for treating pain

Country Status (20)

Country Link
EP (1) EP0833935A1 (en)
JP (1) JPH11507530A (en)
KR (1) KR19990022414A (en)
CN (1) CN1192246A (en)
AR (1) AR004494A1 (en)
AU (1) AU6263696A (en)
BR (1) BR9608746A (en)
CA (1) CA2223246A1 (en)
CZ (1) CZ392497A3 (en)
EE (1) EE9700326A (en)
HU (1) HUP9901191A2 (en)
IL (1) IL122415A0 (en)
IN (1) IN181898B (en)
IS (1) IS4628A (en)
NO (1) NO975545L (en)
PL (1) PL323867A1 (en)
SK (1) SK167997A3 (en)
TR (1) TR199701520T1 (en)
WO (1) WO1996040959A1 (en)
ZA (1) ZA964880B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028449A2 (en) * 1997-11-28 1999-06-10 Medical Research Council Yac vectors
WO2000016799A1 (en) 1998-09-23 2000-03-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating chronic pain
US6372489B1 (en) 1998-10-27 2002-04-16 Anticancer, Inc. Method and model for hair pigmentation
EP1127121B1 (en) * 1998-10-27 2005-12-14 Anticancer, Inc. Construction d'une retrovirus exprimant le locus mel de streptomyces, et son expression dans des cellules mammiferes
US6903244B1 (en) 1999-02-26 2005-06-07 University Of Utah Research Foundation Mice which are +/− or −/− for the elastin gene as models for vascular disease
AU2002952993A0 (en) 2002-11-29 2002-12-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic and diagnostic agents
EP1701736A4 (en) 2003-12-24 2008-05-07 Inst Medical W & E Hall THERAPEUTIC AGENTS AND ITS USES
WO2005108981A1 (en) 2004-05-12 2005-11-17 The Walter And Eliza Hall Institute Of Medical Research A method of cell isolation
AU2006261599B2 (en) 2005-06-24 2011-10-06 The Walter & Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same
AU2007275764B2 (en) 2006-07-18 2013-11-14 University Of Utah Research Foundation Methods for treating pain and screening analgesic compounds
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
JP6681826B2 (en) 2013-05-31 2020-04-15 ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション Conotoxin peptides, pharmaceutical compositions and their use
JP6877419B2 (en) 2015-10-27 2021-05-26 ザ ユニバーシティー オブ クイーンズランド Treatment methods and agents useful for them
CN107964047B (en) * 2017-12-18 2018-11-02 哈尔滨工业大学 Chimeric peptide and its synthetic method based on Tyr-Pro-Trp-Phe-NH2 and neurotensin (8-13) and application
CN112891337A (en) * 2021-03-26 2021-06-04 河北医科大学 Application of galangin and its derivatives in preparing medicine for preventing and treating nervous system diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48813A1 (en) * 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules

Also Published As

Publication number Publication date
CA2223246A1 (en) 1996-12-19
NO975545D0 (en) 1997-12-02
WO1996040959A1 (en) 1996-12-19
IS4628A (en) 1997-12-04
ZA964880B (en) 1997-01-07
AU6263696A (en) 1996-12-30
SK167997A3 (en) 1998-05-06
EP0833935A1 (en) 1998-04-08
KR19990022414A (en) 1999-03-25
AR004494A1 (en) 1998-12-16
CN1192246A (en) 1998-09-02
JPH11507530A (en) 1999-07-06
IL122415A0 (en) 1998-06-15
NO975545L (en) 1998-02-04
EE9700326A (en) 1998-06-15
BR9608746A (en) 1999-05-11
IN181898B (en) 1998-10-24
CZ392497A3 (en) 1998-12-16
TR199701520T1 (en) 1998-04-21
PL323867A1 (en) 1998-04-27

Similar Documents

Publication Publication Date Title
HUP9901191A2 (en) Cell line producing analgesic compounds for treating pain
ATE237285T1 (en) MEDICAL IMPLANT
CY1112260T1 (en) CONTROLLED HYDROCONUT PACKAGES
IS4083A (en) Composition of pharmaceutical substances, method of manufacture thereof, and use as pharmaceuticals
HUP9700322A2 (en) Preparation and methods for providing longer local anesthesia
DE69813908D1 (en) USE OF CREATINE SUBSTANCES FOR TREATING BONE AND CARTILAGE CELLS AND TISSUE
JO1613B1 (en) N-(3- hydroxy-4- piperidinyl) (dihydrobenzofuran, dihydro -2h- benzopyran or dihydrobenzodioxin) carboxamide derivatives
HUP9800794A2 (en) The use of (S)-oxybutynin and (S)-desethyloxybutynin for the production of pharmaceutical preparations for the treatment of urinary incontinence and the preparation of the compounds
DE69814394D1 (en) USE OF LEVOBUPIVACAIN
DE69626996D1 (en) DEGRADABLE MATERIAL AND METHOD FOR THE PRODUCTION THEREOF
ATE144420T1 (en) USE OF RILUZOLE TO TREAT PARKINSON'S AND PARKINSON'S SYNDROMES
DE69622265D1 (en) TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS
ATE316779T1 (en) IMPLANTS FOR THE CONTROLLED RELEASE OF PHARMACEUTICAL ACTIVE INGREDIENTS AND METHOD FOR THE PRODUCTION
ATE234088T1 (en) TAXOL FOR THE TREATMENT OF LYMPHOMAS AND BREAST CANCER AND TO REDUCE MULTI-DRUG RESISTANCE TO TAXOL
DE69424777D1 (en) 3,4-DIARYLCHROMANE FOR TREATING DERMATITIS
BG104797A (en) Use of dexmedetomi dine for sedative effect in patients in an intensive care unit
NZ330944A (en) Peptide derivatives
DE69426530D1 (en) PHARMACEUTICAL COMPOSITION TO PROMOTE TISSUE HEALING AND REGENERATION AND PHARMACEUTICAL SET
HRP20010133B1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
MXPA00010254A (en) The treatment of sexual dysfunction in certain patient groups.
TR199801184T2 (en) New compounds with analgesic action.
ATE331523T1 (en) STATIN THERAPY TO IMPROVE MAINTAINING COGNITIVE FUNCTION
DE69434002D1 (en) 2,3 DIARYL-1-BENZOPYRAME FOR TREATING DERMATITIS
ATE248218T1 (en) HUMAN HYPERTROPHIC CHRONDROCYTE CELL LINES
UA7192A (en) Method for massage of biologically active points and instrument for massage of biologically active points developed by v. shushkovskyi